Trial NCT03621982

View at ClinicalTrials.gov 
Org. Study IDs: ADCT-301-103
Secondary IDs: 2019-003132-23

Last trial update was posted on 2023-03-17

MeSH Interventions

Pembrolizumab

MeSH Conditions

Carcinoma Carcinoma, Renal Cell Fallopian Tube Neoplasms Pancreatic Neoplasms Triple Negative Breast Neoplasms

Other Conditions

Advanced Solid Tumors With Literature Evidence of CD25(+) Treg Content Bladder Cancer Colo-rectal Cancer Esophageal Cancer Fallopian Tube Cancer Gastric Cancer Head and Neck Cancer Squamous Cell Carcinoma Melanoma Non-small Cell Lung Cancer Ovarian Cancer Pancreas Cancer Renal Cell Carcinoma Triple-negative Breast Cancer

Stopping Reasons

Cami in combination with pembrolizumab in solid tumors showed signals of immunomodulatory activity. However, the signals were insufficiently compelling at the tested dose/schedule to justify continuation of the study.

Limitations And Caveats

N/A

Result Publications

N/A

Annotations

Category Annotations
No annotators decided on categories yet

Intervention Annotations
# Outdated Intervention Condition
Name Route DrugBank ID